Kamal Joshi is a Principal Scientist and Group Leader in Discovery Biotherapeutics at Bristol Myers Squibb (BMS), where he leads the development of next-generation multispecific antibodies and T-cell engager therapies for cancer. His work focuses on protein engineering, antibody discovery, and AI-enabled biologics innovation to advance novel immunotherapies. Prior to BMS, he conducted antibody engineering research at Genentech and earned his Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.
· Developed a multispecific TCE platform integrating tumor targeting, T-cell engagement, and costimulation.
· Optimized TCEs enhanced T-cell activation, persistence, and tumor cell killing in preclinical studies.
· Integrated costimulation may improve the potency and durability of TCEs for solid tumors